ArticleNPJ precision oncology2025
Prolonged response to dual immune checkpoint blockade in patients with advanced solid tumors: a case series.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Immunotherapy has substantially changed the landscape of cancer. We present five patients with advanced cancer who had failed standard-of-care therapies, participated in clinical trials with anti-CTLA4/anti-PD1 therapy, and had prolonged progression-free survival (PFS): Pt1: microsatellite stable (MSS) rectal adenocarcinoma (34+ months); Pt2: high grade neuroendocrine carcinoma (68 months); Pt3: MSS colon adenocarcinoma (38+ months); Pt4: deficient mismatch repair (dMMR) prostate adenocarcinoma (68+ months); Pt5: high-grade neuroendocrine carcinoma (69+ months). Grade 3 immune-related adverse events (irAEs; n = 4) were treated successfully, allowing further treatment with the anti-PD1 therapy. Positron-emission tomography (PET)/computed tomography (CT) scans demonstrated complete response in 3 of 4 patients whose CT scans had shown partial response. These cases highlight the exceptional outcomes of selected patients with advanced cancer treated with immunotherapy and exemplify the value of personalized patient monitoring/management of irAEs while assessing response to immunotherapy. Ongoing trials evaluate biomarkers that predict response and toxicity associated with immunotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.